Immunogenicity of the COVID-19 BNT162b2 vaccine in adolescents and young adults with cystic fibrosis낭포성 섬유증이 있는 청소년 및 젊은 성인에서 COVID-19 BNT162b2 백신의 면역원성Article Published on 2022-05-012022-09-11 Journal: Journal of cystic fibrosis : official journal of t [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, [키워드] AEs antibody association binding domain BNT162b2 BNT162b2 vaccine Control COVID-19 Cystic cystic fibrosis dose epidemiological fibrosis Genotype healthy control healthy controls immunogenic immunogenicity investigated Local median median age medications NAbs Neutralizing no significant difference no significant differences P-value parameters Patient patients phenotype Protein RBD reactogenicity SARS-CoV-2 SARS-CoV-2 BNT162b2 second dose severity Severity of disease systemic adverse event the disease U/mL Vaccine [DOI] 10.1016/j.jcf.2022.04.004 PMC 바로가기 [Article Type] Article
Antibody response to the COVID-19 ChAdOx1nCov-19 and BNT162b vaccines after temporary suspension of DMARD therapy in immune-mediated inflammatory disease (RESCUE)면역매개염증질환(RESCUE)에서 DMARD 치료를 일시적으로 중단한 후 COVID-19 ChAdOx1nCov-19 및 BNT162b 백신에 대한 항체 반응Randomized Controlled Trial Published on 2022-05-012022-09-11 Journal: RMD Open [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료기술, 치료제, [키워드] Adult patients Antibody Response Antibody responses antirheumatic agents AstraZeneca AZ vaccine baseline biologic BNT162b Control control group control groups controls COVID-19 csDMARD dose Final first and second dose first dose first vaccination group groups IgG Immune-mediated immunogenicity inflammatory disease Messenger RNA multicentre not significantly different Patient Pfizer Protein randomised randomised controlled trial registration number response S1/S2 SARS-CoV-2 antibody SARS-CoV-2 IgG SARS-CoV2 second dose second vaccination Seroconversion seroconversion rate seroconversion rates significantly lower the antibody response the mean therapy titre titres U/mL vaccination Vaccine were measured [DOI] 10.1136/rmdopen-2022-002301 PMC 바로가기 [Article Type] Randomized Controlled Trial
CA 15-3 prognostic biomarker in SARS-CoV-2 pneumoniaSARS-CoV-2 폐렴의 CA 15-3 예후 바이오마커Observational Study Published on 2022-04-252022-09-11 Journal: Scientific Reports [Category] COVID19(2023년), SARS, 바이오마커, 임상, 진단, [키워드] 2019 95% CI 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adjusted adjusted odds ratio Admission analyzed Antigen Biobank blood sample Blood samples C-reactive protein Complication Concentration coronavirus coronavirus disease correlated Course COVID-19 CRP D-dimer death died discharge discharged evaluated fibrosis help higher risk IL6 In-hospital in-hospital complication in-hospital complications increased risk Infection Intensive intensive care interleukin interleukin 6 lung damage lung involvement Male sex marker men NT-proBNP observational study Occurrence Older age Other oxygen Oxygen therapy Patient patients with SARS-CoV-2 Pneumonia predict Prognosis prognostic biomarker Prognostic factor Prognostic marker recruited Registered required respiratory retrospective Risk factors SARS-CoV-2 SARS-CoV-2 pneumonia severe acute respiratory syndrome Coronavirus severity supplemental oxygen Support the mean troponin T troponine U/mL [DOI] 10.1038/s41598-022-10726-7 PMC 바로가기 [Article Type] Observational Study
High failure rate of ChAdOx1-nCoV19 immunization against asymptomatic infection in healthcare workers during a Delta variant surgeDelta 변종 급증 중 의료 종사자의 무증상 감염에 대한 ChAdOx1-nCoV19 면역의 높은 실패율Article Published on 2022-04-012022-09-11 Journal: Nature Communications [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] acute respiratory syndrome Anti-spike Asymptomatic asymptomatic infection Breakthrough infection ChAdOx1 ChAdOx1-nCoV19 Cohort confidence confidence interval delta variant effective Effectiveness expected group healthcare healthcare worker Healthcare workers herd immunity Immunity immunization induction Infection infection rate infection rates inhibiting interval less neutralization activity outbreak Population Range reducing respiratory risk SEROLOGICAL STUDY serology Severe acute respiratory syndrome severe disease severe infections Transmission U/mL uninfected unlikely vaccination Vaccine Vaccine failure were infected wildtype [DOI] 10.1038/s41467-022-29404-3 PMC 바로가기 [Article Type] Article
Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers의료 종사자에서 비활성화된 COVID-19 백신의 안전성 및 면역원성Article Published on 2022-04-012022-09-11 Journal: Journal of medical virology [Category] COVID19(2023년), MERS, SARS, 진단, 치료법, [키워드] administration adverse event Adverse reaction Adverse reactions age antibodies antibody Antibody Response Antibody responses appear booster doses comparable Concentration conducted convalescent plasma convalescent serum CoronaVac coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 vaccine domain dose Effective vaccines geometric mean geometric mean concentration GMC Health care Health care worker health care workers hospital IgG immunization immunogenicity Immunoglobulin Immunoglobulin G inactivated Inactivated vaccine incidence Infection injection Injection-site pain Local myalgia N protein nucleocapsid nucleocapsid protein Pain pandemic participant positive prospective cohort study Protein RBD Receptor-binding domain recruited regimen Safe Safety SARS-CoV-2 Serious Adverse Event Serious Adverse Events seroconversion rate seroconversion rates Spike protein tested the RBD Total total antibodies total antibody U/mL Vaccine virus waned [DOI] 10.1002/jmv.27458 PMC 바로가기 [Article Type] Article
A method comparison of three immunoassays for detection of neutralizing antibodies against SARS-CoV-2 receptor-binding domain in individuals with adenovirus type-5-vectored COVID-19 vaccination아데노바이러스 5형 벡터가 매개된 COVID-19 백신 접종을 받은 개인에서 SARS-CoV-2 수용체 결합 도메인에 대한 중화 항체 검출을 위한 3가지 면역분석법 비교Article Published on 2022-04-012022-09-11 Journal: Journal of Clinical Laboratory Analysis [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, 치료제, [키워드] Adenovirus Analysis analyzed Bland-Altman plot chemiluminescence chemiluminescent immunoassay clinical contribute correlation correlations COVID-19 vaccination decrease domain Efficacy enzyme enzyme-linked immunosorbent enzyme-linked immunosorbent assay enzyme-linked immunosorbent assays exclusion humoral immunoassay individual limit limit of detection linear medium method comparison methodology Neutralizing antibodies neutralizing antibody performance performed positive Precision Quantitative RBD Receptor-binding domain SARS-CoV-2 semi-quantitative serum sample serum samples Standard technology U/mL vaccination Vaccine vaccine efficacy Viral viral neutralization [DOI] 10.1002/jcla.24306 PMC 바로가기 [Article Type] Article
Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab인플릭시맙과 베돌리주맙으로 치료받은 염증성 장질환 환자에서 SARS-CoV-2 백신 2회 투여 후 항체 붕괴, T 세포 면역 및 돌발성 감염Article Published on 2022-03-162022-09-11 Journal: Nature Communications [Category] MERS, SARS, 유전자 메커니즘, 진단, [키워드] anti-S anti-TNF antibody antibody concentration BNT162b2 Breakthrough infection breakthrough infections ChAdOx1 ChAdOx1 nCoV-19 Concentration dose drug geometric mean half-live immune responses Immunity impair induce Inflammatory bowel disease infliximab Influenza influenza vaccination integrin nCoV Necrosis of BNT162b2 p value Patient patients patients treated pneumococcal predicted protective immunity RBD required respiratory respiratory infection risk SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 infections SARS-CoV-2 vaccine sustained T cell T cell response treated treatment groups tumour necrosis factor U/mL vaccination vaccination schedule vaccine doses vaccine-induced immune response vedolizumab [DOI] 10.1038/s41467-022-28517-z PMC 바로가기 [Article Type] Article
Evaluation of antibody response after COVID-19 vaccination of healthcare workers의료진의 코로나19 예방접종 후 항체반응 평가Article Published on 2022-03-012022-09-11 Journal: Journal of medical virology [Category] MERS, SARS, 진단, 치료법, [키워드] addition age antibody antibody levels Antibody Response antibody response against Antibody titer Antibody titers BMI BMI values body mass body mass index CoronaVac COVID-19 COVID-19 vaccination develop dose effective Elecsy Elecsys evaluated examined Factor female Gender HCW healthcare healthcare worker Healthcare workers immune response Immunity Inactivated vaccine individuals infected with COVID-19 interquartile range IQR male median age nucleocapsid protein obese participant Participants participated postvaccination RBD RBD protein Receptor binding Receptor binding domain Receptor-binding domain SARS-CoV-2 SARS-CoV-2 spike protein second dose second dose of vaccine Seropositivity Smokers smoking Spike protein the receptor-binding domain the SARS-CoV-2 U/mL Vaccine Volunteer volunteers was determined was measured [DOI] 10.1002/jmv.27420 PMC 바로가기 [Article Type] Article
Recurrent COVID-19 Polymerase Chain Reaction (PCR) Positivity in 2 Patients During the Current Health Care System Crisis현재 의료 시스템 위기 동안 2명의 환자에서 반복적인 COVID-19 중합효소 연쇄 반응(PCR) 양성Case Reports Published on 2022-02-142022-09-11 Journal: The American journal of case reports [Category] COVID19(2023년), SARS, 변종, 치료기술, [키워드] anti-SARS-CoV-2 immunoglobulin Care cause chain Chain Reaction complementary Computed tomography Corona Corona virus coronavirus disease Coronavirus disease 2019 coronavirus variants COVID-19 crisis crisis management criterion current detect Diagnostic method diagnostic methods diagnostics exacerbate follow-up period genetic material Health Health care Health crisis healthcare IgG Immunoglobulin Immunoglobulin G individual infectious information less management Misdiagnosis new SARS-CoV-2 Other outcome pandemic Patient PCR polymerase chain polymerase chain reaction positive positive test result public health crisis quarantine question raised reaction Recurrent Reinfection respiratory risk rRT-PCR RT-PCR SARS-CoV-2 SARS-CoV-2 variants Seroconversion serological test Serological tests serology testing Severe acute respiratory syndrome Severe acute respiratory syndrome corona virus-2 syndrome System test result the patient U/mL variants variants of SARS-CoV-2 virus [DOI] 10.12659/AJCR.935414 PMC 바로가기 [Article Type] Case Reports
Comparison of Anti-SARS-CoV-2 S1 Receptor-Binding Domain Antibody Immunoassays in Health Care Workers Before and After the BNT162b2 mRNA VaccineBNT162b2 mRNA 백신 전과 후 의료 종사자의 Anti-SARS-CoV-2 S1 수용체 결합 도메인 항체 면역 측정법의 비교Article Published on 2022-02-032022-09-11 Journal: American journal of clinical pathology [Category] COVID19(2023년), SARS, 치료기술, 치료법, [키워드] 2019-nCoV anti-RBD antibody antibody concentration antibody production assays biomedical engineering blood sample Blood samples BNT162b2 BNT162b2 mRNA BNT162b2 vaccine booster dose Care collected COVID-19 DiaSorin dose Elecsy Elecsys Engineering evaluated Health Health care IgG immunoassay immunoassays Immunoglobulin Immunoglobulin G induce interquartile range LIAISON median medians New nucleocapsid protein Nucleocapsid proteins Pfizer Pfizer-BioNTech professional RBD Receptor-binding domain Roche Roche Diagnostics S-RBD SARS-CoV-2 SARS-CoV-2 IgG SARS-COV-2 infection Siemens Healthineers Snibe Diagnostics spike glycoprotein statistically significant tested the median the receptor-binding domain the vaccine Type of antibody U/mL vaccination Vaccine were measured worker [DOI] 10.1093/ajcp/aqab107 PMC 바로가기 [Article Type] Article